Evommune says Phase 2a trial shows EVO301 cuts EASI 55% at Week 12 in atopic dermatitis

By Public Technologies
  • Evommune presented additional Phase 2a proof-of-concept data for EVO301 in moderate-to-severe atopic dermatitis at EADV 2026.
  • Trial results showed clear symptom improvement versus placebo, with responses continuing to build weeks after the second dose.
  • Safety profile was broadly comparable to placebo, supporting further development and differentiation from existing biologics.
  • Plans set to start a global, dose-optimized Phase 2b trial using a subcutaneous formulation in mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261001558140) on October 01, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk